Amedisys, Inc. (NASDAQ:AMED) Short Interest Up 42.9% in July

Amedisys, Inc. (NASDAQ:AMED) saw a large increase in short interest during the month of July. As of July 31st, there was short interest totaling 3,200,000 shares, anincreaseof42.9% from the July 15th total of 2,240,000 shares. Based on an average daily trading volume, of 482,600 shares, the short-interest ratio is currently 6.6 days. Currently,10.0% of the company’s stock are short sold. Currently,10.0% of the company’s stock are short sold. Based on an average daily trading volume, of 482,600 shares, the short-interest ratio is currently 6.6 days.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen downgraded shares of Amedisys from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 24th. One research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $100.50.

Institutional Investors Weigh In On Amedisys

Several hedge funds have recently bought and sold shares of AMED. Norges Bank acquired a new stake in Amedisys in the 2nd quarter valued at about $88,761,000. Pentwater Capital Management LP lifted its stake in Amedisys by 178.3% in the 4th quarter. Pentwater Capital Management LP now owns 1,180,000 shares of the health services provider’s stock valued at $107,132,000 after purchasing an additional 756,000 shares during the last quarter. Neuberger Berman Group LLC acquired a new stake in Amedisys in the 2nd quarter valued at about $26,597,000. Amundi lifted its stake in Amedisys by 838,295.7% in the 1st quarter. Amundi now owns 192,831 shares of the health services provider’s stock valued at $17,931,000 after purchasing an additional 192,808 shares during the last quarter. Finally, AQR Arbitrage LLC lifted its stake in Amedisys by 59.1% in the 4th quarter. AQR Arbitrage LLC now owns 471,965 shares of the health services provider’s stock valued at $42,812,000 after purchasing an additional 175,311 shares during the last quarter. 94.36% of the stock is currently owned by institutional investors and hedge funds.

Amedisys Trading Up 0.0%

Amedisys stock opened at $101.01 on Thursday. The firm has a 50-day moving average of $98.32 and a 200-day moving average of $94.90. Amedisys has a one year low of $82.15 and a one year high of $101.02. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.36 and a quick ratio of 1.36. The company has a market cap of $3.32 billion, a price-to-earnings ratio of 39.30, a P/E/G ratio of 1.34 and a beta of 0.89.

Amedisys (NASDAQ:AMED) last issued its earnings results on Tuesday, July 29th. The health services provider reported $1.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.39 by $0.15. Amedisys had a net margin of 3.56% and a return on equity of 12.91%. The business had revenue of $621.86 million during the quarter, compared to the consensus estimate of $614.61 million. During the same period last year, the business posted $0.98 EPS. Amedisys’s revenue was up 5.2% on a year-over-year basis. On average, equities analysts expect that Amedisys will post 4.4 earnings per share for the current fiscal year.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.